A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

SST2-positive Neuroendocrine Neoplasms · Neuroendocrine Tumors · Neuroendocrine Neoplasm

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Crinetics Study Site, Phoenix, Arizona, United States
Crinetics Study Site, Duarte, California, United States
Crinetics Study Site, Newport Beach, California, United States
Crinetics Study Site, Orange, California, United States
Crinetics Study Site, San Francisco, California, United States
Crinetics Study Site, Denver, Colorado, United States
Crinetics Study Site, New Haven, Connecticut, United States
Crinetics Study Site, Atlanta, Georgia, United States
Crinetics Study Site, Lexington, Kentucky, United States
Crinetics Study Site, Metairie, Louisiana, United States
Crinetics Study Site, Detroit, Michigan, United States
Crinetics Study Site, Grand Rapids, Michigan, United States
Crinetics Study Site, Rochester, Minnesota, United States
Crinetics Study Site, New York, New York, United States
Crinetics Study Site, Philadelphia, Pennsylvania, United States
Crinetics Study Site, Philadelphia, Pennsylvania, United States
Crinetics Study Site, Austin, Texas, United States
Crinetics Study Site, Houston, Texas, United States
Crinetics Study Site, Irving, Texas, United States
Crinetics Study Site, Salt Lake City, Utah, United States
Crinetics Study Site, Charlottesville, Virginia, United States
Crinetics Study Site, Fairfax, Virginia, United States
Crinetics Study Site, Barcelona, Spain
Crinetics Study Site, Barcelona, Spain
Crinetics Study Site, Madrid, Spain
Crinetics Study Site, Madrid, Spain

View source on ClinicalTrials.gov